StandardX raises £10M seed to scale rare isotope production for medicine and fusion

StandardX says its goal is to establish a more reliable and resilient European supply chain for critical rare materials. Its proprietary accelerator system is intended to replace infrastructure tied to specific isotopes with a single platform capable of producing a wider portfolio from a standard industrial footprint. The design also supports distributed production, enabling manufacturing to be sited closer to where the isotopes are used.

According to the company, global isotope production currently depends on a small number of ageing facilities and machines with limited output. Isotopes are used across healthcare, energy and other sectors.

StandardX is initially targeting isotopes used in cancer diagnosis and treatment, including materials required for targeted alpha therapies. It plans to supply its first isotopes to a medical research partner.

Paymob, Corridor and Spott announced funding rounds spanning payments infrastructure, AI health benefits and recruitment software.